News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,579 Results
Type
Article (41729)
Company Profile (473)
Press Release (661377)
Section
Business (208452)
Career Advice (2010)
Deals (35954)
Drug Delivery (97)
Drug Development (83363)
Employer Resources (169)
FDA (16344)
Job Trends (15052)
News (352224)
Policy (33002)
Tag
Academia (2619)
Alliances (50711)
Alzheimer's disease (1302)
Approvals (16284)
Artificial intelligence (154)
Bankruptcy (361)
Best Places to Work (11785)
Biotechnology (355)
Breast cancer (193)
Cancer (1405)
Cardiovascular disease (117)
Career advice (1677)
Cell therapy (301)
Clinical research (66463)
Collaboration (508)
Compensation (263)
COVID-19 (2601)
C-suite (114)
Data (1413)
Diabetes (176)
Diagnostics (6230)
Earnings (86121)
Employer resources (147)
Events (113496)
Executive appointments (402)
FDA (17028)
Funding (447)
Gene therapy (213)
GLP-1 (634)
Government (4419)
Healthcare (19024)
Infectious disease (2693)
Inflammatory bowel disease (118)
Interviews (309)
IPO (16618)
Job creations (3696)
Job search strategy (1430)
Layoffs (445)
Legal (7941)
Lung cancer (202)
Lymphoma (100)
Manufacturing (214)
Medical device (13362)
Medtech (13367)
Mergers & acquisitions (19487)
Metabolic disorders (479)
Neuroscience (1642)
NextGen Class of 2024 (6738)
Non-profit (4539)
Northern California (1716)
Obesity (273)
Opinion (202)
Patents (118)
People (57823)
Phase I (20855)
Phase II (29337)
Phase III (21690)
Pipeline (523)
Postmarket research (2598)
Preclinical (8937)
Radiopharmaceuticals (252)
Rare diseases (278)
Real estate (5998)
Regulatory (22112)
Research institute (2406)
Resumes & cover letters (351)
Southern California (1490)
Startups (3747)
United States (15604)
Vaccines (580)
Weight loss (199)
Date
Today (34)
Last 7 days (599)
Last 30 days (2488)
Last 365 days (36296)
2024 (36087)
2023 (41016)
2022 (52276)
2021 (56763)
2020 (54929)
2019 (47425)
2018 (35700)
2017 (33025)
2016 (32351)
2015 (38401)
2014 (32194)
2013 (27114)
2012 (29222)
2011 (29866)
2010 (27996)
Location
Africa (731)
Arizona (203)
Asia (38671)
Australia (6432)
California (3917)
Canada (1458)
China (310)
Colorado (175)
Connecticut (187)
Europe (84344)
Florida (537)
Georgia (135)
Illinois (398)
Indiana (227)
Maryland (642)
Massachusetts (3093)
Michigan (174)
Minnesota (296)
New Jersey (1124)
New York (1098)
North Carolina (802)
Northern California (1716)
Ohio (148)
Pennsylvania (934)
South America (1105)
Southern California (1490)
Texas (563)
Utah (110)
Washington State (413)
703,579 Results for "cara therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024
·
16 min read
Pharm Country
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).
June 12, 2024
·
3 min read
Business
Cara Therapeutics Reports First Quarter 2024 Financial Results
Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the first quarter ended March 31, 2024.
May 13, 2024
·
10 min read
Business
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close.
May 6, 2024
·
1 min read
Pharm Country
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
April 2, 2024
·
1 min read
Business
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.
March 4, 2024
·
16 min read
Business
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.
February 12, 2024
·
1 min read
Pharm Country
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Cara Therapeutics, Inc. today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT.
March 7, 2024
·
2 min read
Press Releases
Cara Therapeutics Announces Exploration of Strategic Alternatives
July 11, 2024
·
2 min read
Drug Development
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses.
January 22, 2024
·
6 min read
1 of 70,358
Next
